Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Rank

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|December 13, 2023
A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell TransplantationMax Bittrich, Katharina Kriegsmann, Carola Tietze-Stolley, et al.
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|October 30, 2023
Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB StudyKatharina Kriegsmann, Max Bittrich, Sandra Sauer, et al.
The Lancet. Haematology|February 1, 2024
High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trialElisabeth Schorb, Lisa Kristina Isbell, Andrea Kerkhoff, et al.
Leukemia|October 21, 2020
A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapyEva M Weissinger, Jochen Metzger, Michael Schleuning, et al.
The Lancet. Haematology|March 6, 2026
Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trialLeo Ruhnke, Christoph Schliemann, Jan-Henrik Mikesch, et al.
Trials|November 4, 2021
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AMLSonia Jaramillo, Johannes Krisam, Lucian Le Cornet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2024
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance LeukemiaChristoph Röllig, Björn Steffen, Christoph Schliemann, et al.
American Journal of Hematology|January 6, 2026
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction TherapyStefan Markus Dendorfer, Katharina Schmidt-Brücken, Michael Kramer, et al.
Lancet (London, England)|July 6, 2024
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trialPeter Borchmann, Justin Ferdinandus, Gundolf Schneider, et al.
Blood|April 14, 2026
Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidationEnise Ceran, Sonia Jaramillo, Anne Kathrin Merbach, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|December 13, 2023
A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell TransplantationMax Bittrich, Katharina Kriegsmann, Carola Tietze-Stolley, et al.
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|October 30, 2023
Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB StudyKatharina Kriegsmann, Max Bittrich, Sandra Sauer, et al.
The Lancet. Haematology|February 1, 2024
High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trialElisabeth Schorb, Lisa Kristina Isbell, Andrea Kerkhoff, et al.
Leukemia|October 21, 2020
A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapyEva M Weissinger, Jochen Metzger, Michael Schleuning, et al.
The Lancet. Haematology|March 6, 2026
Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trialLeo Ruhnke, Christoph Schliemann, Jan-Henrik Mikesch, et al.
Trials|November 4, 2021
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AMLSonia Jaramillo, Johannes Krisam, Lucian Le Cornet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2024
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance LeukemiaChristoph Röllig, Björn Steffen, Christoph Schliemann, et al.
American Journal of Hematology|January 6, 2026
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction TherapyStefan Markus Dendorfer, Katharina Schmidt-Brücken, Michael Kramer, et al.
Lancet (London, England)|July 6, 2024
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trialPeter Borchmann, Justin Ferdinandus, Gundolf Schneider, et al.
Blood|April 14, 2026
Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidationEnise Ceran, Sonia Jaramillo, Anne Kathrin Merbach, et al.
Pageof 8